Manni Mohyuddin: Every day in my clinic, there is selection bias in favor of an increase in PFS for CAR T-cell therapy

Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:

“Every day in my clinic, there is selection bias in favor of an increase in Progression-free survival (PFS) for CAR T-cell therapy.

• Aggressive disease, rapidly rising light chains: Give Bispecific T-cell engager (BiTE).
• Indolent progressions, planning for next treatment in advance: Think CAR T-cell therapy.

Cilta-cel real-world Progression-free survival (PFS) will be stellar for this reason, in my opinion.

We have many debates on CART versus Bispecific T-cell engager (BiTE). But for those who desperately imminently need therapy now for progressions- BiTE beat CART out of the park.”

Source: Manni Mohyuddin/Twitter